[go: up one dir, main page]

CL2017002498A1 - Piridopirimidinonas y su uso como modulares del receptor nmda - Google Patents

Piridopirimidinonas y su uso como modulares del receptor nmda

Info

Publication number
CL2017002498A1
CL2017002498A1 CL2017002498A CL2017002498A CL2017002498A1 CL 2017002498 A1 CL2017002498 A1 CL 2017002498A1 CL 2017002498 A CL2017002498 A CL 2017002498A CL 2017002498 A CL2017002498 A CL 2017002498A CL 2017002498 A1 CL2017002498 A1 CL 2017002498A1
Authority
CL
Chile
Prior art keywords
pyridopyrimidinones
modulators
nmda receptor
compounds
formula
Prior art date
Application number
CL2017002498A
Other languages
English (en)
Inventor
Matthew Volgraf
Elisia Villemure
Guosheng Wu
Aijun Lu
Yu Jiang
Benjamin Sellers
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017002498A1 publication Critical patent/CL2017002498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>La invención se refiere a compuestos piridopirimidinona de fórmula I: o sales farmacéuticamente aceptables de los mismos, en los que X, R1 , R2 , R3 , R4 , R5 y R6 son tal como se define en la presente memoria, así como composiciones farmacéuticas que comprenden dichos compuestos y métodos de tratamiento que utilizan dichos compuestos.</p>
CL2017002498A 2015-04-15 2017-10-03 Piridopirimidinonas y su uso como modulares del receptor nmda CL2017002498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2015076617 2015-04-15

Publications (1)

Publication Number Publication Date
CL2017002498A1 true CL2017002498A1 (es) 2018-04-20

Family

ID=55809078

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002498A CL2017002498A1 (es) 2015-04-15 2017-10-03 Piridopirimidinonas y su uso como modulares del receptor nmda

Country Status (19)

Country Link
US (1) US10280165B2 (es)
EP (1) EP3283487B1 (es)
JP (2) JP6847851B2 (es)
KR (1) KR20170137137A (es)
CN (1) CN107531696B (es)
AU (1) AU2016248886B2 (es)
BR (1) BR112017021083A2 (es)
CA (1) CA2982217A1 (es)
CL (1) CL2017002498A1 (es)
CO (1) CO2017009989A2 (es)
CR (1) CR20170462A (es)
IL (1) IL254921B (es)
MX (1) MX373162B (es)
PE (1) PE20180316A1 (es)
PH (1) PH12017501876A1 (es)
RU (1) RU2717665C2 (es)
SG (1) SG11201708294YA (es)
UA (1) UA120647C2 (es)
WO (1) WO2016166078A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004540A (es) 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
JP6847851B2 (ja) 2015-04-15 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
RS60834B1 (sr) 2015-12-09 2020-10-30 Cadent Therapeutics Inc Modulatori heteroaromatskog nmda receptora i njihove upotrebe
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
EP4223760B1 (en) 2018-08-03 2025-06-04 Novartis AG Heteroaromatic nmda receptor modulator and uses thereof
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
PH12022552933A1 (en) 2020-05-04 2024-02-12 Amgen Inc Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
MXPA05013142A (es) * 2003-06-20 2006-03-17 Chiron Corp Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20080194616A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
RU2666532C2 (ru) * 2013-06-19 2018-09-11 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она или пирролопиридин/пиримидин-2-она
MX2016004540A (es) * 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
JP6847851B2 (ja) 2015-04-15 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Also Published As

Publication number Publication date
BR112017021083A2 (pt) 2018-07-03
PH12017501876A1 (en) 2018-02-26
JP2021046428A (ja) 2021-03-25
AU2016248886B2 (en) 2020-09-10
CR20170462A (es) 2018-02-01
EP3283487A1 (en) 2018-02-21
CA2982217A1 (en) 2016-10-20
CN107531696B (zh) 2021-03-16
EP3283487B1 (en) 2019-10-16
MX2017013101A (es) 2018-01-30
US20180127414A1 (en) 2018-05-10
JP2018511627A (ja) 2018-04-26
AU2016248886A1 (en) 2017-10-12
MX373162B (es) 2020-04-21
CN107531696A (zh) 2018-01-02
IL254921A0 (en) 2017-12-31
PE20180316A1 (es) 2018-02-09
JP6847851B2 (ja) 2021-03-24
HK1245259A1 (zh) 2018-08-24
IL254921B (en) 2021-02-28
RU2717665C2 (ru) 2020-03-24
UA120647C2 (uk) 2020-01-10
CO2017009989A2 (es) 2018-01-05
KR20170137137A (ko) 2017-12-12
WO2016166078A1 (en) 2016-10-20
RU2017139254A (ru) 2019-05-15
US10280165B2 (en) 2019-05-07
SG11201708294YA (en) 2017-11-29
RU2017139254A3 (es) 2019-09-30

Similar Documents

Publication Publication Date Title
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CO2018007443A2 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
ECSP17069696A (es) Compuestos novedosos
SV2017005381A (es) Compuestos de imidazopiridazina
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina